You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 417 Design and rationale of a phase 1 study evaluating AMG 256, a novel, targeted, IL-21 receptor agonist and anti-PD-1 antibody, in patients with advanced solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
417 Design and rationale of a phase 1 study evaluating AMG 256, a novel, targeted, IL-21 receptor agonist and anti-PD-1 antibody, in patients with advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020156023
Dec 20202405
Jan 20211802
Feb 20216407
Mar 2021126018
Apr 2021228029
May 202126011
Jun 20210017
Jul 2021008
Aug 20210012
Sep 20210024
Oct 202168030
Nov 202148021
Dec 202144010
Jan 20224006
Feb 20225205
Mar 2022118017
Apr 202210209
May 202212007
Jun 2022157019
Jul 20225202
Aug 2022114010
Sep 202272010
Oct 202296011
Nov 202288015
Dec 20229208
Jan 20238404
Feb 2023106016
Mar 202376015
Apr 202382013
May 202396010
Jun 20236608
Jul 202352010
Aug 20239009
Sep 2023114012
Oct 2023138016
Nov 2023148019
Dec 202310008
Jan 2024112012
Feb 2024114010
Mar 2024146020
Apr 20249607
May 202498012
Jun 2024140010
Jul 2024160011
Aug 2024134012
Sep 2024110014
Oct 2024186030
Nov 2024176030
Dec 2024200023
Jan 2025166018
Feb 202524011
Mar 20250011
Apr 20250014
May 2025006
Jun 20250012
Total49190739